Novo Nordisk $69m Plant Conversion For New Diabetes Drug

Novo Nordisk says the $69 investment in its Danish plant will convert capacity ready for its new GLP-1 analogue and is a further commitment to Danish manufacturing.

Planned to be operational by the first quarter of 2014, the DK380m plant conversion will, according to the company, create 50 new jobs at the Kalundborg facility, adding to the current workforce of over 2,400 people.

In a statement, Per Valstorp, Senior VP of Product Supply said “the Kalundborg investment reaffirms our long-term commitment to creating and maintaining jobs in Denmark.”